PTEN and PIK3CA Mutation Positive Breast Neuroendocrine Carcinoma Treated with Molecularly Targeted Therapy Including Capivasertib
The Tohoku Journal of Experimental Medicine · 2026 · 270 (1) · 181-186
DOI: 10.1620/tjem.2026.j019 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Tohoku Journal of Experimental Medicine, 2026. Verfasst von Kyoko Shimoyama und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Takatsuki General Hospital. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Mutation, Breast Neoplasms, Carcinoma, Neuroendocrine. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Breast neuroendocrine carcinoma (BNEC) is rare (< 0.1%) but is clinically important due to its rapidly progression, treatment-resistant, and poor prognosis despite being hormone receptors-positive. No effective treatment for BNEC has been established. BNEC is little recognized, so it may be overlooked as an invasive carcinoma of no special type. However, an early diagnosis of BNEC is critical, as it allows for comprehensive genomic profiling (CGP). We present a case of a woman in her 40s with heterochronic bilateral breast cancer, who was ultimately diagnosed with BNEC due to the rapid disease progression with bone, liver, and lung metastases, during semiannual follow-up. CGP revealed PTEN, PIK3CA, and ESR1 mutations as well as a high tumor mutational burden (TMB-high). While she received everolimus, abemaciclib, and bevacizumab, capivasertib was most effective. BNEC is rare, but an early diagnosis, based on clinical course, is key for CGP and correct treatment selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Takatsuki General Hospital.
- Department of Pathology, Takatsuki General Hospital.
Zitieren
APA
Shimoyama, K., & Ikura, Y. (2026). PTEN and PIK3CA Mutation Positive Breast Neuroendocrine Carcinoma Treated with Molecularly Targeted Therapy Including Capivasertib. The Tohoku Journal of Experimental Medicine, 270(1), 181-186. https://doi.org/10.1620/tjem.2026.j019
Vancouver
Shimoyama K, Ikura Y. PTEN and PIK3CA Mutation Positive Breast Neuroendocrine Carcinoma Treated with Molecularly Targeted Therapy Including Capivasertib. The Tohoku Journal of Experimental Medicine. 2026;270(1):181-186. doi:10.1620/tjem.2026.j019
BibTeX
@article{Shimoyama2026,
author = {Shimoyama, Kyoko and Ikura, Yoshihiro},
title = {PTEN and PIK3CA Mutation Positive Breast Neuroendocrine Carcinoma Treated with Molecularly Targeted Therapy Including Capivasertib},
journal = {The Tohoku Journal of Experimental Medicine},
year = {2026},
volume = {270},
number = {1},
pages = {181--186},
doi = {10.1620/tjem.2026.j019}
}
EUVIMED